Get started
Prosegur Cash: Head and Shoulders and earningsH&S pattern and earnings outcome on July 31 may drag the price down to new historical minimum levels at 0.58, following long-term bearish channel. Also, second wave in Spain swelling may put pressure downwards on the stock price due to the company's main business: ATM's cash, which in covid19 days people are less keen on using physical money and prefer paying with card. However, Prosegur Cash is trying to keep floating capital with dividend reinvestments and buying its own capital. No analyst recommends to sell and 8 recommend to buy. Q1, CASH reduced profits 10.7% and made -3.9% sales. CASH also blames the currencies' effect to its earnings, so keep in mind that when covid exploded euro was up to 1.14 and now, after European Union took action with its funding 750.000 million, eurusd is up to 1.17. So watch out its Q2 earnings, but also get ready for Q3 in case Q2 are disappointing.
BME:CASHShort
by alexinve
LOGISTA: Shaping perfect bearish #headandshouldersAlthough its profits amounted at a record level last year 2019 at €165 million (+5.1% YoY), a head and shoulders figure appears in the short term maybe to drag the company to 14.10 zone at the end of July or beginning of August. Pharma logistics and convinience products division had a very good behaviour. EBITDA was €81.5 million (+11.3% YoY) However, in the first fiscal semester, LOGISTA experienced -11.8% profits YoY even though revenues have been stable. Ebitda is down -9%, although they've applied IFRS 16 and then it's up 1.6%, as a consequence of it. If the company decides to pay dividend as every year at the end of August, maybe LOG will go up for the dividend appetite from 14.19€ zone. It is important to note that payout in 2019 was 93.6% and in 2020 they've increased it to 95%. Big payout, folks!
BME:LOGShort
by alexinve
CAIXABANK: Approx. #Bearish #batpattern on its way & Q2 earningsThe bank's results are due on July 24th. JP Morgan and Wells Fargo saw sharp declines on profits (-51% and -71% respectively) yesterday and I expect Spanish banks will be unable to avoid them too. Besides, CABK has been the bank who's best performed in the short-term post-covid era, so we could expect bigger downward corrections than those in Santander or BBVA once their results come in. Barclays "saves" CABK and SAN's rating but still forecasts a -52% decline on profits for the sector although in my opinion, I expect -60% minimum. From the technical point of view, an approximated bat pattern is being formed and its figure may be ended either today or tomorrow at level 2.10-2.12. Once it is completed, the bank's share price may drop towards 1.80 level (0.5 Fib level) or 0.382 Fib livel (1.878) in case earnings readings are better than expected.
BME:CABKShort
by alexinve
Deoleo: Very risky although volatility may make see some gainsDEOLEO is back in the Spanish stockmarket and with higher average volume than the previous 3 months. It has cut its debt by 42% and earned €4.5 million in Q1, compared to -€7.5 million in losses in Q12019. It is a very risky investment and next results are set to be published around the first days of August (3/8/20). I would call for a long position until first stop 0.23 and then make another technical analysis. Right now there is a bearish bat pattern threatening the stock until 0.1630 or second support at 0.1458.
BME:OLELong
by alexinve
FAES FARMA: Last touch to lower bound of the bullish channel?Tomorrow might be the day where FAES FARMA goes to the lower bound for the last time at 3.60€ level and from there goes up to Target Price 4.50€. It can close the triangle formed from April 24 to today going down to 3€ or spiking up to 4.50€ from June 4 on. That would be from a short-term perspective. From a long-term one, optimum technical entry price is at 3.40-3.45€. The stock is immersed in a bullish channel since December 7, 2012. 2019 was the fourth consecutive year of increasing profits, up to historical maximum €64 million (+24% than 2018). EBITDA was up +26.6%.
BME:FAELong
by alexinve
Grifols: A new bullish channel up to +18%?Focused on hemoderivatives (blood plasma), Grifols is great value by most of investors. Even though the company might be one day spitted by any scandal on how it is gathering the plasma in the US, americans have got a high stake on it and today it is focusing on an hyperimmune immunoglobulin with specific antibodies against the SARS-CoV-2 virus. Grifols estimated an impact on its accounts of €200 million and many rating houses have downgraded the stock. Its 2019's profits were up 4.8% to 625 million and an EBITDA of 1,434 million (+17,3% YoY). In 2020, Q1 Net profits were up 63% and EBITDA 14.9%. Results on its tests will be presented in July (the mandatory 14 days to see whether the virus is gone or not). We may experience volatility in the price of the company until July 01. According to some news, Grifols' margins were not attractive and that is why the correction of the share price has taken place. Technically speaking, the company might be immersed in a bullish channel started on March 16 and closing out a triangle started on Feb 20. We could expect the share price go at least up to 29.40 level in the next days. Best price to enter Grifols might be 27€. Also, note that when markets are down, Grifols is up acting like a safe haven asset.
BME:GRFLong
by alexinve